Cover Image

Liraglutide Activates Glucagon-Like Peptide 1 Receptor to Attenuate Hyperglycemia through Endogenous Beta-Endorphin in Diabetic Rats

Liraglutide, an acylated analog of glucagon-like peptide 1 (GLP-1), could improve glycemic control in diabetes. Moreover, endogenous opioid peptides play a role in blood sugar regulation. Since GLP-1 receptors are also expressed in extra-pancreatic tissues, this study investigates the effect of lira...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kai-Chun Cheng (Author), Ying-Xiao Li (Author), Po-Chuen Shieh (Author), Juei-Tang Cheng (Author), Chia-Chen Hsu (Author)
Format:	Book
Published:	MDPI AG, 2020-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain
by: Chia-Chen Hsu, et al.
Published: (2022)

Glucagon-like peptide-1 analogue, liraglutide, delays onset and reduces severity of experimental autoimmune encephalitis in Lewis rats
by: Brian DellaValle, et al.
Published: (2016)

Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction
by: Brent A. McLean, et al.
Published: (2022)

Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells
by: Jui-Ting Chang, et al.
Published: (2017)

Biotransformation of beta-endorphin and possible therapeutic implications
by: Naghmeh Hajarol Asvadi, et al.
Published: (2014)

The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome
by: Shenhai Liu, et al.
Published: (2020)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017)

Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes
by: Yan Tong, et al.
Published: (2023)

Glucagon-Like Peptide-1 Triggers Protective Pathways in Pancreatic Beta-Cells Exposed to Glycated Serum
by: Alessandra Puddu, et al.
Published: (2013)

Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets
by: Thao D.V. Le, et al.
Published: (2023)

Glucagon-like peptide 1 (GLP-1)
by: T.D. Müller, et al.
Published: (2019)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024)

Plasma levels of beta-endorphin and serotonin in response to specific spinal based exercises
by: O. Sokunbi, et al.
Published: (2008)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
by: Samantha L. Price, MRes, et al.
Published: (2015)

Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management
by: Mariya Kalinkova, et al.
Published: (2023)

Effects of exercise on glucagon-like peptide-1 (GLP-1)
by: Shin-ya Ueda, et al.
Published: (2013)

Identification of Andrographolide as an Agonist of Bile Acid TGR5 Receptor in a Cell Line to Demonstrate the Reduction in Hyperglycemia in Type-1 Diabetic Rats
by: Yingxiao Li, et al.
Published: (2023)

THE IMPACT OF LAVENDER AROMATHERAPY ON PAIN INTENSITY AND BETA-ENDORPHIN LEVELS IN POST-CAESAREAN MOTHERS
by: Yohana Putri Apryanti, et al.
Published: (2017)

The effects of low and high glycemic index foods on exercise performance and beta-endorphin responses
by: Nikolaidis Michalis G, et al.
Published: (2011)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
by: Cheng D, et al.
Published: (2022)

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023)

Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease
by: Tianyu Wang, et al.
Published: (2024)

Myricetin Increases Circulating Adropin Level after Activation of Glucagon-like Peptide 1 (GLP-1) Receptor in Type-1 Diabetic Rats
by: Ying-Xiao Li, et al.
Published: (2022)

Pyrogens Enhance β-Endorphin Release in Hypothalamus and Trigger Fever That Can Be Attenuated by Buprenorphine
by: Shu-Ming Tsai, et al.
Published: (2003)

C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice
by: Daoqi Tang, et al.
Published: (2018)

Possibilities of using analogues of glucagon-like peptide-1 in various disease entities
by: Weronika Bielka, et al.
Published: (2021)

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
by: I. N. Dyakov, et al.
Published: (2021)

Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice
by: Tulika Arora, et al.
Published: (2016)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
by: Laurie L. Baggio, et al.
Published: (2021)

Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
by: Michal Rabenda, et al.
Published: (2024)

Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin
by: Hsuan-Wen Chou, et al.
Published: (2022)

Neural regulation of hindlimb muscle contraction-induced glucagon-like peptide-1 and peptide YY secretion in rats
by: Shin-ya Ueda, et al.
Published: (2015)

Co-storage and release of insulin-like peptide-5, glucagon-like peptide-1 and peptideYY from murine and human colonic enteroendocrine cells
by: Lawrence J. Billing, et al.
Published: (2018)

Effect of Glucagon-like peptide-1 receptor agonists on dyslipidemia in type 2 diabetes
by: Elizabeth A. Cristiano, et al.
Published: (2020)

Impact of Glucagon-like Peptide-1 Receptor Agonists on Intestinal Epithelial Cell Barrier
by: Takizawa Y., et al.
Published: (2024)

Enteroendocrine-derived glucagon-like peptide-2 controls intestinal amino acid transport
by: Jennifer Lee, et al.
Published: (2017)

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
by: Simon C. Cork, et al.
Published: (2015)

The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
by: Anja Harej Hrkać, et al.
Published: (2024)

Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
by: Yeonhee Hong, et al.
Published: (2019)

Use of Glucagon-like peptide 2 (GLP-2) analogs in inflammatory bowel disease
by: Dobromiła Osuch, et al.
Published: (2024)